The startup plans to use the latest round of funding to expand the team, bullet-proof the platform and the product for user adoption followed by commercials, and regulatory clearances for global markets.
“Our goal is to develop intelligent, scalable and affordable disease screening solutions which can empower medical experts and facilitate quality healthcare delivery to the masses. Our initial focus is on the solutions for the screening tests so that we can positively impact a larger population not only in India but globally,” said Rohit Kumar Pandey, Co-founder and CEO, SigTuple.
Manthana- SigTuple’s AI platform
The core product of the company is “Manthana” – a continuous learning platform powered by AI for healthcare. It allows SigTuple to ingest visual medical data from different devices and build a longitudinal memory. It has capability to train, validate and execute AI and ML powered models to classify various objects of interest, detect diseases and compute the metrics for reporting. The metrics provided by the platform are supported by visual evidence which eliminates the need of the medical expert to sit next to the patient, medical device or biological sample.
The platform also exposes an interface for the medical experts to get feedback and annotations which enables continuous learning with new and changing visual medical data.
SigTuple claims that its solutions will allow labs and hospitals to scale by implementing a hub and spoke model where the medical experts can operate from hub and devices can be installed in spokes. The solution will be available at a very affordable price and will enable labs to adopt technology without changing the hardware. Currently, SigTuple is using Manthana to provide solutions for automated analysis of peripheral blood smear, urine and semen sample, retinal scans and chest x-rays.
“SigTuple is one of those home-grown companies which has potential to compete globally. I strongly believe that the products they are developing will revolutionise healthcare delivery not only in India but globally”, says Binny Bansal, Group CEO, Flipkart.
In October 2015, the company had raised $740,000 from Sachin Bansal, Binny Bansal, Accel Partners, Ashok Bareja, Nirupa Bareja and Debanjan Mukherjee. Currently, the startup is working with large hospitals and labs and a group of medical experts in various fields to develop its solutions.
